Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center

European Journal of Cancer

Volumn 49, Issue 15, 2013, Pages 3076-3082

  Wiesweg, Marcel ^a   Ting, Saskia ^a   Reis, Henning ^a   Worm, Karl ^a   Kasper, Stefan ^a   Tewes, Mitra ^a   Welt, Anja ^a   Richly, Heike ^a   Meiler, Johannes ^a   Bauer, Sebastian ^a   Hense, Jörg ^a   Gauler, Thomas C ^a   Köhler, Jens ^a   Eberhardt, Wilfried E ^a   Darwiche, Kaid ^a   Freitag, Lutz ^a   Stamatis, Georgios ^a   Breitenbücher, Frank ^a   Wohlschlaeger, Jeremias ^a   Theegarten, Dirk ^a   Derks, Cordula ^a   Cortes Incio, Diana ^a   Linden, Gabriele ^a   Skottky, Silke ^a   Lütkes, Peter ^a   Dechêne, Alexander ^a   Paul, Andreas ^a   Markus, Peter ^b   Schmid, Kurt W ^a   Schuler, Martin ^a,c   more..

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b ELISABETH KRANKENHAUS ESSEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Biomarker; Colorectal cancer; Lung cancer; Mutation; Personalised medicine; Profiling

Indexed keywords

ALK PROTEIN; B RAF KINASE; DDR2 KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ALGORITHM; AMPLICON; ARTICLE; CANCER CENTER; CANCER PATIENT; CANCER TISSUE; COLORECTAL CANCER; COST BENEFIT ANALYSIS; DISEASE COURSE; FEASIBILITY STUDY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENE TRANSLOCATION; GERMANY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LOSS OF FUNCTION MUTATION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PATIENT PARTICIPATION; PREEMPTIVE BIOMARKER PROFILING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOMARKER; COLORECTAL CANCER; LUNG CANCER; MUTATION; PERSONALISED MEDICINE; PROFILING;

CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DRUG DISCOVERY; FEASIBILITY STUDIES; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84884902113     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.014     Document Type: Article

References (18)

1. N.B.L. Thangue, and D.J. Kerr Predictive biomarkers: a paradigm shift towards personalized cancer medicine Nat Rev Clin Oncol 8 2011 587 596
2. T. Li, H.-J. Kung, and P.C. Mack Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies J Clin Oncol 8 2013 1039 1049
3. N. Normanno, S. Tejpar, and F. Morgillo Implications for KRAS status and EGFR-targeted therapies in metastatic CRC Nat Rev Clin Oncol 6 2009 519 527
4. K. Suda, K. Tomizawa, and T. Mitsudomi Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation Cancer Metastasis Rev 29 2010 49 60
5. T.A. Yap, S.K. Sandhu, and P. Workman Envisioning the future of early anticancer drug development Nat Rev Cancer 10 2010 514 523
6. M. Buyse, S. Michiels, and D.J. Sargent Integrating biomarkers in clinical trials Expert Rev Mol Diagn 11 2011 171 182
7. A.C. Wolff, M.E.H. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 2007 18 43
8. H.-U. Schildhaus, L.C. Heukamp, and S. Merkelbach-Bruse Definition of a fluorescence in-situ hybridization score identifies high-and low-level FGFR1 amplification types in squamous cell lung cancer Mod Pathol 25 2012 1473 1480
9. L.S. Steelman, W.H. Chappell, and S.L. Abrams Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging Aging (Albany, NY) 3 2011 192 222
10. J. Weiss, M.L. Sos, and D. Seidel Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer Sci Transl Med 2 2010 62ra93
11. P.S. Hammerman, M.L. Sos, and A.H. Ramos Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Cancer Discov 1 2011 78 89
12. L. Ding, G. Getz, and D.A. Wheeler Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 2008 1069 1075
13. The Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 489 2012 519 525
14. E.R. Fearon Molecular genetics of colorectal cancer Annu Rev Pathol Mech 6 2011 479 507
15. The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
16. B.S. Taylor, N. Schultz, and H. Hieronymus Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
17. M. Gerlinger, A.J. Rowan, and S. Horswell Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
18. A.J. Atherly, and D.R. Camidge The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers Br J Cancer 106 2012 1100 1106